Revisiting Androgen Receptor Signaling in Breast Cancer
The Oncologist · 08.05.2023 · 28 (5) · 383-391
DOI: 10.1093/oncolo/oyad049 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.03.2023. Verfasst von Charles Dai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Aberrant estrogen receptor (ER) signaling is central to the pathogenesis of many breast cancers. Like ER, the androgen receptor (AR) is a steroid nuclear receptor that is frequently expressed in breast cancer and has long been considered an attractive therapeutic target. Although androgens were historically employed in the treatment of breast cancer, this strategy has largely fallen out of favor with the advent of modern anti-estrogens, due to virilizing effects from androgens, as well as concerns that androgens could be converted to estrogens to fuel tumor growth. Recent molecular advances, however, including the development of selective androgen receptor modulators, have renewed interest in targeting the AR. Yet androgen signaling in breast cancer remains incompletely understood, and preclinical studies have yielded conflicting and sometimes contradictory evidence regarding the role of AR, resulting in clinical investigations into both AR agonists and antagonists. It is increasingly recognized that AR may very well be context-specific, with divergent actions in ER-positive versus ER-negative disease. Here, we will summarize our current understanding of AR biology and insights from recent investigations into AR–directed therapies in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
- Department of Medicine, Harvard Medical School, Boston, MA, USA.
- Department of Medicine, Ludwig Center at Harvard, Boston, MA, USA.
Förderung
- NCI NIH HHS
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Dai, C., & Ellisen, L. W. (2023). Revisiting Androgen Receptor Signaling in Breast Cancer. The Oncologist, 28(5), 383-391. https://doi.org/10.1093/oncolo/oyad049
Vancouver
Dai C, Ellisen LW. Revisiting Androgen Receptor Signaling in Breast Cancer. The Oncologist. 2023;28(5):383-391. doi:10.1093/oncolo/oyad049
BibTeX
@article{Dai2023,
author = {Dai, Charles and Ellisen, Leif W},
title = {Revisiting Androgen Receptor Signaling in Breast Cancer},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {5},
pages = {383--391},
doi = {10.1093/oncolo/oyad049}
}
EUVIMED